MannKind Corporation Stock Nasdaq
Equities
US56400P2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-08 | Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 | MT |
Sales 2024 * | 272M 372M | Sales 2025 * | 319M 435M | Capitalization | 1.18B 1.61B |
---|---|---|---|---|---|
Net income 2024 * | 35M 47.84M | Net income 2025 * | 70M 95.69M | EV / Sales 2024 * | 3.41 x |
Net cash position 2024 * | 248M 340M | Net cash position 2025 * | 273M 373M | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
40
x | P/E ratio 2025 * |
19.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.88% |
Latest transcript on MannKind Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 16-03-13 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 22-09-30 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 18-11-26 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 19-12-31 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 03-09-30 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |